Literature DB >> 10234506

SMN protein analysis in fibroblast, amniocyte and CVS cultures from spinal muscular atrophy patients and its relevance for diagnosis.

A L Patrizi1, F Tiziano, S Zappata, M A Donati, G Neri, C Brahe.   

Abstract

Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder caused by the homozygous absence of the telomeric copy of the survival motor neuron (SMNt) gene, due to deletion, gene conversion or point mutation. SMNt and its homologous centromeric copy (SMNc) encode the SMN protein, which is diffusely present in the cytoplasm and in dot-like structures, called gems, in the nucleus. We have studied the SMN protein in different cell cultures, including fibroblasts, amniocytes and CVS cells from SMA individuals and controls. By immunofluorescence analysis we found a marked reduction in the number of gems in fibroblasts, amniocytes and chorionic villus cells of all SMA patients and foetuses, independent of the type of the genetic defect. We also show that immunolocalisation of the SMN protein may be a useful tool for the characterisation of particular patients of uncertain molecular diagnosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10234506     DOI: 10.1038/sj.ejhg.5200286

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  15 in total

1.  The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells.

Authors:  Markus Riessland; Lars Brichta; Eric Hahnen; Brunhilde Wirth
Journal:  Hum Genet       Date:  2006-05-25       Impact factor: 4.132

2.  SMN transcript levels in leukocytes of SMA patients determined by absolute real-time PCR.

Authors:  Francesco Danilo Tiziano; Anna Maria Pinto; Stefania Fiori; Rosa Lomastro; Sonia Messina; Claudio Bruno; Antonella Pini; Marika Pane; Adele D'Amico; Alessandro Ghezzo; Enrico Bertini; Eugenio Mercuri; Giovanni Neri; Christina Brahe
Journal:  Eur J Hum Genet       Date:  2010-01       Impact factor: 4.246

3.  Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy.

Authors:  Mimoun Azzouz; Thanh Le; G Scott Ralph; Lucy Walmsley; Umrao R Monani; Debbie C P Lee; Fraser Wilkes; Kyriacos A Mitrophanous; Susan M Kingsman; Arthur H M Burghes; Nicholas D Mazarakis
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

4.  Clinical and molecular cross-sectional study of a cohort of adult type III spinal muscular atrophy patients: clues from a biomarker study.

Authors:  Francesco D Tiziano; Rosa Lomastro; Lorena Di Pietro; Maria Barbara Pasanisi; Stefania Fiori; Carla Angelozzi; Emanuela Abiusi; Corrado Angelini; Gianni Sorarù; Alessandra Gaiani; Tiziana Mongini; Liliana Vercelli; Gessica Vasco; Giuseppe Vita; Gian Luca Vita; Sonia Messina; Luisa Politano; Luigia Passamano; Grazia Di Gregorio; Cristina Montomoli; Chiara Orsi; Angela Campanella; Renato Mantegazza; Lucia Morandi
Journal:  Eur J Hum Genet       Date:  2012-10-17       Impact factor: 4.246

Review 5.  Assays for the identification and prioritization of drug candidates for spinal muscular atrophy.

Authors:  Jonathan J Cherry; Dione T Kobayashi; Maureen M Lynes; Nikolai N Naryshkin; Francesco Danilo Tiziano; Phillip G Zaworski; Lee L Rubin; Jill Jarecki
Journal:  Assay Drug Dev Technol       Date:  2014-08       Impact factor: 1.738

6.  Treatment of spinal muscular atrophy cells with drugs that upregulate SMN expression reveals inter- and intra-patient variability.

Authors:  Eva Also-Rallo; Laura Alías; Rebeca Martínez-Hernández; Lidia Caselles; María J Barceló; Montserrat Baiget; Sara Bernal; Eduardo F Tizzano
Journal:  Eur J Hum Genet       Date:  2011-05-25       Impact factor: 4.246

7.  A screen for regulators of survival of motor neuron protein levels.

Authors:  Nina R Makhortova; Monica Hayhurst; Antonio Cerqueira; Amy D Sinor-Anderson; Wen-Ning Zhao; Patrick W Heiser; Anthony C Arvanites; Lance S Davidow; Zachary O Waldon; Judith A Steen; Kelvin Lam; Hien D Ngo; Lee L Rubin
Journal:  Nat Chem Biol       Date:  2011-06-19       Impact factor: 15.040

Review 8.  Spinal muscular atrophy.

Authors:  Susan T Iannaccone; Stephen A Smith; Louise R Simard
Journal:  Curr Neurol Neurosci Rep       Date:  2004-01       Impact factor: 5.081

9.  WRAP53 is essential for Cajal body formation and for targeting the survival of motor neuron complex to Cajal bodies.

Authors:  Salah Mahmoudi; Sofia Henriksson; Irene Weibrecht; Stephen Smith; Ola Söderberg; Staffan Strömblad; Klas G Wiman; Marianne Farnebo
Journal:  PLoS Biol       Date:  2010-11-02       Impact factor: 8.029

Review 10.  Therapeutics development for spinal muscular atrophy.

Authors:  Charlotte J Sumner
Journal:  NeuroRx       Date:  2006-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.